CA3109897A1 - Vaccination contre le coronavirus a l'aide d'un vaccin sabin - Google Patents

Vaccination contre le coronavirus a l'aide d'un vaccin sabin Download PDF

Info

Publication number
CA3109897A1
CA3109897A1 CA3109897A CA3109897A CA3109897A1 CA 3109897 A1 CA3109897 A1 CA 3109897A1 CA 3109897 A CA3109897 A CA 3109897A CA 3109897 A CA3109897 A CA 3109897A CA 3109897 A1 CA3109897 A1 CA 3109897A1
Authority
CA
Canada
Prior art keywords
poliovirus
poliomyelitis vaccine
vaccine
inactivated
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3109897A
Other languages
English (en)
Inventor
Qiyi Xie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/098,449 external-priority patent/US20210322542A1/en
Application filed by Individual filed Critical Individual
Publication of CA3109897A1 publication Critical patent/CA3109897A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32671—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3109897A 2020-04-11 2021-01-20 Vaccination contre le coronavirus a l'aide d'un vaccin sabin Pending CA3109897A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063008664P 2020-04-11 2020-04-11
US63/008,664 2020-04-11
US202063010678P 2020-04-15 2020-04-15
US63/010,678 2020-04-15
US202063013561P 2020-04-22 2020-04-22
US63/013,561 2020-04-22
US17/098,449 2020-11-15
US17/098,449 US20210322542A1 (en) 2020-04-11 2020-11-15 Vaccination against coronavirus with poliomyelitis vaccine
PCT/US2021/014253 WO2021206783A1 (fr) 2020-04-11 2021-01-20 Vaccination contre le coronavirus avec un vaccin contre la poliomyélite

Publications (1)

Publication Number Publication Date
CA3109897A1 true CA3109897A1 (fr) 2021-06-10

Family

ID=76321159

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3109897A Pending CA3109897A1 (fr) 2020-04-11 2021-01-20 Vaccination contre le coronavirus a l'aide d'un vaccin sabin

Country Status (4)

Country Link
EP (1) EP3914293B1 (fr)
JP (2) JP2022524251A (fr)
CN (1) CN115697397A (fr)
CA (1) CA3109897A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA010057B1 (ru) * 2004-08-27 2008-06-30 Панацея Биотек Лтд. Инактивированная полиомиелитная вакцина, полученная из штамма сейбина вируса полиомиелита

Also Published As

Publication number Publication date
EP3914293A1 (fr) 2021-12-01
CN115697397A (zh) 2023-02-03
EP3914293B1 (fr) 2024-07-03
JP2022524251A (ja) 2022-05-02
EP3914293A4 (fr) 2022-03-16
JP2023060048A (ja) 2023-04-27

Similar Documents

Publication Publication Date Title
Shi et al. An overview of COVID-19
Halsey et al. Search for poliovirus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom
Oliveira et al. Immune response in COVID-19: What do we currently know?
Wu et al. Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice
US11590221B2 (en) Dengue vaccine unit dose and administration thereof
Diaz-San Segundo et al. Synonymous deoptimization of foot-and-mouth disease virus causes attenuation in vivo while inducing a strong neutralizing antibody response
Ruben et al. Influenza in a partially immunized aged population: effectiveness of killed Hong Kong vaccine against infection with the England strain
Kooshkaki et al. Coronavirus disease 2019: a brief review of the clinical manifestations and pathogenesis to the novel management approaches and treatments
US20210315988A1 (en) Vaccination against coronavirus with poliomyelitis vaccine
Ferreira et al. SARS-CoV-2, Zika viruses and mycoplasma: Structure, pathogenesis and some treatment options in these emerging viral and bacterial infectious diseases
Zhu et al. Biological features of human influenza A (H3N8) viruses in China
US20220226462A1 (en) Vaccination against coronavirus with poliomyelitis vaccine
EP3914293B1 (fr) Vaccination contre le coronavirus avec un vaccin contre la poliomyélite
Nomier et al. Distinctive Therapeutic Strategies against Corona Virus19 (COVID-19): A Pharmacological Review.
Dhurvey et al. Two worst pandemics-Spanish Flu and COVID-19: a review
Jati et al. Coronavirus Diseases (COVID-19): Features, Epidemiology, Mutational Variations and Treatments Across India.
Varghese et al. Pandemic of the era: covid-19–an overview
US11426461B2 (en) Methods for preventing dengue and hepatitis A
Khodaparast et al. Threats to Arrangements COVID-19
Tarro AntiCOVID-19 Vaccines for Children
Abdu et al. Biological property of novel coronavirus SARS-CoV-2 (2019-nCoV)
Al Awwadi et al. Research Open
Gall Routine maternal immunizations for all pregnant women
Cascella et al. Continuing Education Activity
Mishra et al. Pharmaceutical and Nano Sciences